[Failure of bone marrow autograft in metastatic malignant adrenalcortical carcinoma].
BACKGROUND
Despite different therapeutic modalities (surgery, hormones therapy, chemotherapy), 5-year survival in patients with malignant adrenocortical carcinoma remains only 10% to 20%. Bone marrow grafts may be proposed to intensify treatment.


METHODS
In a 29-year-old patient with adrenocortical carcinoma with metastases to the lung and bone, an adjuvant bone marrow graft using peripheral stem cells was unsuccessful. Recurrence was observed at 3 months and overall survival was 2 years.


CONCLUSIONS
Our case illustrates the feasibility of this approach but also emphasizes the relatively poor results obtains with only 2 years survival (1 year after the bone marrow graft), comparable with other classical modalities reported in the literature.
Andrès
E
E
Service de Médecine Interne et Nutrition, Hôpital de Hautepierre, Strasbourg. medecineinterne.chuhautepierre@wanadoo.fr
Kurtz
J E
JE
Lioure
B
B
Quetin
P
P
Maloisel
F
F
Schlienger
J L
JL
Dufour
P
P
D000306:Adrenal Cortex Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery*; D000328:Adult; D001859:Bone Neoplasms / Q000556:secondary; D002277:Carcinoma / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery*; D017809:Fatal Outcome; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008175:Lung Neoplasms / Q000556:secondary; D009362:Neoplasm Metastasis; D014182:Transplantation, Autologous; D017211:Treatment Failure